Tibet Weixinkang Medicine Co., Ltd. (SHA:603676)
China · Delayed Price · Currency is CNY 8.90
-0.11 (-1.22%)
Jun 11, 2026, 3:00 PM CST
Tibet Weixinkang Medicine Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 216.65 | 232.85 | 246.17 | 214.02 | 176.96 | 95.91 |
Depreciation & Amortization | 49.46 | 49.46 | 52.89 | 48.57 | 40.93 | 34.09 |
Other Amortization | 2.79 | 2.79 | 8.38 | 1.78 | 12.03 | 2.07 |
Loss (Gain) From Sale of Assets | 0.08 | 0.08 | -0.01 | 0.44 | -0.16 | -0.06 |
Asset Writedown & Restructuring Costs | 1.26 | 1.26 | 17.63 | 0.13 | 14.16 | 3.25 |
Loss (Gain) From Sale of Investments | -34.96 | -34.96 | -20.34 | -24.42 | -15.76 | -11.32 |
Provision & Write-off of Bad Debts | -2.12 | -2.12 | -0.33 | -2.13 | 0.23 | -1.55 |
Other Operating Activities | 58.68 | 4.98 | 3.22 | 1.4 | -0.52 | 5.23 |
Change in Accounts Receivable | 8.29 | 8.29 | 13.11 | 34.56 | -25.4 | 24.4 |
Change in Inventory | -18.27 | -18.27 | -6.32 | -6.5 | -9.17 | -3.3 |
Change in Accounts Payable | -77.72 | -77.72 | 42.08 | -7.42 | 49.08 | -1.44 |
Change in Other Net Operating Assets | -2.88 | -2.88 | 3.68 | 4.43 | 21.38 | 20.7 |
Operating Cash Flow | 223.03 | 185.53 | 372.78 | 241.12 | 246.15 | 170.69 |
Operating Cash Flow Growth | -27.07% | -50.23% | 54.61% | -2.05% | 44.21% | 27.67% |
Capital Expenditures | -85.59 | -83.92 | -58.18 | -70.81 | -77.69 | -55.6 |
Sale of Property, Plant & Equipment | 0.01 | 0.01 | - | 0.05 | 0.22 | 0.32 |
Investment in Securities | 41 | 41 | -174.92 | -334.01 | 166.89 | -110.19 |
Other Investing Activities | -22.86 | 22.16 | 23.14 | 15.56 | 15.8 | 12.75 |
Investing Cash Flow | -67.44 | -20.75 | -209.96 | -389.21 | 105.21 | -152.71 |
Long-Term Debt Repaid | - | -4.02 | -9.56 | -4.6 | -3.99 | -6.15 |
Net Debt Issued (Repaid) | -4.02 | -4.02 | -9.56 | -4.6 | -3.99 | -6.15 |
Issuance of Common Stock | - | - | - | - | - | 53.32 |
Repurchase of Common Stock | - | - | -30 | - | -3.17 | -0.44 |
Common Dividends Paid | -157.24 | -163.44 | -177.85 | -97.84 | -68.66 | -40.19 |
Other Financing Activities | -2.78 | - | - | - | - | -0.27 |
Financing Cash Flow | -164.04 | -167.45 | -217.4 | -102.44 | -75.82 | 6.27 |
Foreign Exchange Rate Adjustments | -0.82 | -0.45 | 0.49 | 0.63 | - | - |
Net Cash Flow | -9.27 | -3.12 | -54.09 | -249.9 | 275.55 | 24.25 |
Free Cash Flow | 137.44 | 101.62 | 314.61 | 170.3 | 168.46 | 115.09 |
Free Cash Flow Growth | -43.18% | -67.70% | 84.73% | 1.09% | 46.37% | 45.04% |
Free Cash Flow Margin | 11.83% | 8.95% | 24.20% | 12.88% | 12.04% | 11.13% |
Free Cash Flow Per Share | 0.32 | 0.24 | 0.73 | 0.40 | 0.39 | 0.28 |
Cash Income Tax Paid | 123.47 | 116.33 | 116.9 | 139.38 | 132.85 | 104.32 |
Levered Free Cash Flow | 68.82 | 14.78 | 184.56 | 84.69 | 51.84 | 128.62 |
Unlevered Free Cash Flow | 68.98 | 14.92 | 184.7 | 84.9 | 51.95 | 128.7 |
Change in Working Capital | -68.82 | -68.82 | 65.17 | 1.33 | 18.27 | 43.07 |